Moderna Inc
MRNA: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$193.00 | Nmct | Wyytcby |
Moderna Earnings: High-Level Long-Term Guidance Fits Our View; Maintaining $227 Valuation
Moderna reported third-quarter results that were weaker than we had anticipated, largely due to significant manufacturing resizing expenses to allow the firm to adjust to the endemic phase of COVID-19 but retain more flexibility in the future.